Evaxion to present at World Vaccine Congress
Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company, will showcase its AI-Immunology™ platform at the World Vaccine Congress in Washington, D.C., from April 21-24, 2025. The company will deliver two key presentations and host booth #351.
Chief Scientific Officer Birgitte Rønø will present on AI-powered antigen target discovery for cancer vaccines on April 23 at 11:40 ET in Room 206. Additionally, Pär Comstedt, VP of Infectious Disease Vaccine Development, will discuss AI-powered target discovery for infectious disease vaccines at 15:10 ET in Room 202b.
This congress marks one of several scientific, partnering, and investor conferences where Evaxion plans to engage with potential partners and collaborators in Q2 2025. The company will demonstrate its AI-Immunology™ platform's capabilities in vaccine development for both cancers and infectious diseases.
Evaxion Biotech (NASDAQ: EVAX), un'azienda TechBio in fase clinica, presenterà la sua piattaforma AI-Immunology™ al World Vaccine Congress a Washington, D.C., dal 21 al 24 aprile 2025. L'azienda terrà due presentazioni chiave e ospiterà lo stand #351.
Il Chief Scientific Officer Birgitte Rønø presenterà la scoperta di target antigenici potenziata dall'IA per i vaccini contro il cancro il 23 aprile alle 11:40 ET nella Sala 206. Inoltre, Pär Comstedt, VP dello Sviluppo di Vaccini per Malattie Infettive, discuterà la scoperta di target potenziata dall'IA per i vaccini contro le malattie infettive alle 15:10 ET nella Sala 202b.
Questo congresso segna uno dei vari eventi scientifici, di partnership e conferenze per investitori in cui Evaxion prevede di interagire con potenziali partner e collaboratori nel secondo trimestre del 2025. L'azienda dimostrerà le capacità della sua piattaforma AI-Immunology™ nello sviluppo di vaccini sia per i tumori che per le malattie infettive.
Evaxion Biotech (NASDAQ: EVAX), una empresa de TechBio en etapa clínica, presentará su plataforma AI-Immunology™ en el World Vaccine Congress en Washington, D.C., del 21 al 24 de abril de 2025. La compañía realizará dos presentaciones clave y tendrá el stand #351.
La Directora Científica Birgitte Rønø presentará sobre el descubrimiento de objetivos antigénicos impulsado por IA para vacunas contra el cáncer el 23 de abril a las 11:40 ET en la Sala 206. Además, Pär Comstedt, VP de Desarrollo de Vacunas para Enfermedades Infecciosas, discutirá el descubrimiento de objetivos impulsado por IA para vacunas contra enfermedades infecciosas a las 15:10 ET en la Sala 202b.
Este congreso marca uno de varios eventos científicos, de asociación y conferencias para inversores donde Evaxion planea interactuar con posibles socios y colaboradores en el segundo trimestre de 2025. La compañía demostrará las capacidades de su plataforma AI-Immunology™ en el desarrollo de vacunas tanto para cánceres como para enfermedades infecciosas.
Evaxion Biotech (NASDAQ: EVAX)는 임상 단계의 TechBio 회사로서 2025년 4월 21일부터 24일까지 워싱턴 D.C.에서 열리는 세계 백신 회의에서 AI-Immunology™ 플랫폼을 선보일 예정입니다. 이 회사는 두 가지 주요 발표를 진행하고 부스 #351을 운영할 것입니다.
최고 과학 책임자 Birgitte Rønø는 4월 23일 오전 11:40 ET에 206호에서 암 백신을 위한 AI 기반 항원 타겟 발견에 대해 발표할 것입니다. 또한, 감염병 백신 개발 부사장인 Pär Comstedt는 15:10 ET에 202b호에서 감염병 백신을 위한 AI 기반 타겟 발견에 대해 논의할 것입니다.
이번 회의는 Evaxion이 2025년 2분기에 잠재적인 파트너 및 협력자와 교류할 계획인 여러 과학, 파트너십 및 투자자 회의 중 하나입니다. 이 회사는 암과 감염병 모두에 대한 백신 개발에서 AI-Immunology™ 플랫폼의 능력을 시연할 것입니다.
Evaxion Biotech (NASDAQ: EVAX), une entreprise TechBio en phase clinique, présentera sa plateforme AI-Immunology™ lors du World Vaccine Congress à Washington, D.C., du 21 au 24 avril 2025. L'entreprise fera deux présentations clés et accueillera le stand #351.
La Directrice Scientifique Birgitte Rønø présentera la découverte de cibles antigéniques alimentée par l'IA pour les vaccins contre le cancer le 23 avril à 11h40 ET dans la salle 206. De plus, Pär Comstedt, VP du Développement de Vaccins contre les Maladies Infectieuses, discutera de la découverte de cibles alimentée par l'IA pour les vaccins contre les maladies infectieuses à 15h10 ET dans la salle 202b.
Ce congrès marque l'un des nombreux événements scientifiques, de partenariats et de conférences pour investisseurs où Evaxion prévoit d'interagir avec des partenaires et collaborateurs potentiels au deuxième trimestre de 2025. L'entreprise démontrera les capacités de sa plateforme AI-Immunology™ dans le développement de vaccins pour les cancers et les maladies infectieuses.
Evaxion Biotech (NASDAQ: EVAX), ein klinisches TechBio-Unternehmen, wird seine AI-Immunology™ Plattform auf dem World Vaccine Congress in Washington, D.C., vom 21. bis 24. April 2025 präsentieren. Das Unternehmen wird zwei wichtige Präsentationen halten und am Stand #351 vertreten sein.
Die Chief Scientific Officerin Birgitte Rønø wird am 23. April um 11:40 ET im Raum 206 über die KI-gestützte Entdeckung von Antigen-Zielen für Krebsimpfstoffe sprechen. Darüber hinaus wird Pär Comstedt, VP für die Entwicklung von Impfstoffen gegen Infektionskrankheiten, um 15:10 ET im Raum 202b über die KI-gestützte Entdeckung von Zielen für Impfstoffe gegen Infektionskrankheiten diskutieren.
Dieser Kongress ist eines von mehreren wissenschaftlichen, partnerschaftlichen und Investorentreffen, bei denen Evaxion plant, im zweiten Quartal 2025 mit potenziellen Partnern und Mitarbeitern in Kontakt zu treten. Das Unternehmen wird die Fähigkeiten seiner AI-Immunology™ Plattform in der Impfstoffentwicklung sowohl für Krebs als auch für Infektionskrankheiten demonstrieren.
- None.
- None.
- Congress will take place April 21-24, 2025, in Washington, D.C.
COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two presentations and man a booth at the World Vaccine Congress taking place April 21-24, 2025, in Washington, D.C.
Birgitte Rønø, Chief Scientific Officer at Evaxion, will talk about the application of Evaxion’s AI-Immunology™ platform for antigen target discovery for cancer vaccines. Pär Comstedt, Vice President, Infectious Disease Vaccine Development at Evaxion, will present the use of AI-Immunology™ for target discovery for infectious disease vaccines. See details on the presentations below.
The World Vaccine Congress is just one of several scientific, partnering and investor conferences where Evaxion will profile itself and discuss with potential partners and collaborators in the second quarter of 2025.
Throughout the conference, Evaxion invites interested parties to its booth #351 for discussions on effective and accurate target discovery with AI-Immunology™ as well as our pipeline of vaccine candidates for cancers and infectious diseases.
Presentation details:
| Title: | AI-powered antigen target discovery for cancer vaccines |
| Category: | Cancer immunotherapy |
| Location: | Room 206 |
| Date/Time: | April 23, 2025, at 11.40 ET/17.40 CET |
| Presenter: | Birgitte Rønø, Chief Scientific Officer at Evaxion |
| Title: | AI-powered target discovery for infectious disease vaccines |
| Category: | Emerging and re-emerging diseases |
| Location: | Room 202b |
| Date/Time: | April 23, 2025, at 15.10 ET/21.10 CET |
| Presenter: | Pär Comstedt, VP, Infectious Disease Vaccine Development at Evaxion |
Contact information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
What presentations will Evaxion (EVAX) give at the 2025 World Vaccine Congress?
Where can investors meet Evaxion (EVAX) representatives at the World Vaccine Congress 2025?
What technology will Evaxion (EVAX) showcase at the 2025 World Vaccine Congress?
What is Evaxion's (EVAX) conference strategy for Q2 2025?
